Endolymphatic radiotherapy in malignant lymphomas: its potential "prophylactic" value in cases with negative...

Area of Science:

• Oncology
• Radiotherapy
• Nuclear Medicine

Background:

• Hodgkin's disease and non-Hodgkin's lymphoma are significant lymphoid malignancies.
• Endolymphatic radiotherapy using Lipiodol 131I was explored as a treatment modality.
• Patient selection criteria included early-stage (I-III) disease without prior treatment.

Purpose of the Study:

• To evaluate the efficacy of endolymphatic radiotherapy with Lipiodol 131I in patients with Hodgkin's disease and non-Hodgkin's lymphoma.
• To determine if treatment outcomes differ based on lymphographic findings.

Main Methods:

• A retrospective review of 426 patients treated between 1961 and 1969.
• Patients received endolymphatic radiotherapy with Lipiodol 131I.
• Analysis focused on disease stage, lymphographic evidence of nodal involvement, and follow-up data.

Main Results:

• Endolymphatic radiotherapy showed no significant benefit in patients with lymphographic evidence of involved lymph nodes.
• In patients with apparently negative lymphography, this treatment significantly reduced the incidence of relapse in inguino-retroperitoneal nodes.

Conclusions:

• Endolymphatic radiotherapy with Lipiodol 131I is not recommended for lymphoma patients with positive lymphography.
• This radiotherapy may be a valuable option for reducing relapse in specific patient groups with negative lymphography.